Last reviewed · How we verify
Cephazolin
Cephazolin is a Small molecule drug developed by HaEmek Medical Center, Israel. It is currently in Phase 1 development for Bacterial endocarditis, Bacterial pneumonia, Bacterial septicemia. Also known as: Cefamezine.
Cephazolin is a small molecule antibiotic used to treat various bacterial infections, including urinary tract infections, pneumonia, and joint infections. It is classified as a first-generation cephalosporin and is used to prevent group B streptococcal disease around the time of delivery.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cephazolin |
|---|---|
| Also known as | Cefamezine |
| Sponsor | HaEmek Medical Center, Israel |
| Target | Bacterial penicillin-binding protein, Penicillin-binding protein 1A |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Approved indications
- Bacterial endocarditis
- Bacterial pneumonia
- Bacterial septicemia
- Bacterial urinary infection
- Cholangitis
- Genitourinary Tract Infections
- Infection of biliary tract
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disorder of joint
- Lower respiratory tract infection
- Pneumonia due to Streptococcus
- Prevention of Perioperative Infection
- Staphylococcal pneumonia
Common side effects
Key clinical trials
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- IO Vancomycin Spine (PHASE2, PHASE3)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Antibiotics for Prevention of Infection Following Orthognathic Surgery (PHASE4)
- Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic (NA)
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial (PHASE4)
- Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cephazolin CI brief — competitive landscape report
- Cephazolin updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI
Frequently asked questions about Cephazolin
What is Cephazolin?
What is Cephazolin used for?
Who makes Cephazolin?
Is Cephazolin also known as anything else?
What development phase is Cephazolin in?
What does Cephazolin target?
Related
- Target: All drugs targeting Bacterial penicillin-binding protein, Penicillin-binding protein 1A
- Manufacturer: HaEmek Medical Center, Israel — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial endocarditis
- Indication: Drugs for Bacterial pneumonia
- Indication: Drugs for Bacterial septicemia
- Also known as: Cefamezine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing